H. Natter

发表

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.

M. Gaweł, E. Lai, D. Gelinas, 1997, Neurology.

Effect of recombinant human insulin-like growth factor-I on progression of ALS

M. Gaweł, E. Lai, D. Gelinas, 1997, Neurology.

Incidence of cavum septum pellucidum in adults

H. Natter, B. Bogdanoff, 1989, Neurology.

Spinal cord motoneurons express p75NGFR and p145trkB mRNA in amyotrophic lateral sclerosis

J. Seeburger, H. Natter, J. Springer, 1993, Brain Research.

Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies.

A. Damiano, M. Gaweł, D. Patrick, 1999, Medical care.

Recombinant human insulin-like growth factor-I in ALS

M. Gaweł, E. Lai, D. Gelinas, 1996, Neurology.

Malignant hyperthermia susceptibility in X-linked muscle dystrophies.

T. Heiman-Patterson, H. Rosenberg, H. Natter, 1986, Pediatric neurology.

Post-anesthesia uncal herniation secondary to a previously unsuspected temporal glioma.

C. Katsetos, J. Vender, H. Natter, 1995, Journal of forensic sciences.

Cost Effectiveness of Recombinant Human Insulin-Like Growth Factor I Therapy in Patients with ALS

D. Patrick, D. Gelinas, K. Beusterien, 1999, PharmacoEconomics.